Skip to main content
RNA logoLink to RNA
. 2002 Apr;8(4):512–525. doi: 10.1017/s1355838202020617

Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

Jian-Qiu Han 1, David J Barton 1
PMCID: PMC1370272  PMID: 11991644

Abstract

Chronic hepatitis C virus (HCV) infections are a significant cause of morbidity and mortality worldwide. Interferon-alpha2b treatment, alone or in combination with ribavirin, eliminates HCV from some patients, but patients infected with HCV genotype 1 viruses are cured less frequently than patients infected with HCV genotype 2 or 3 viruses. We report that HCV mRNA was detected and destroyed by the interferon-regulated antiviral 2'-5' oligoadenylate synthetase/ ribonuclease L pathway present in cytoplasmic extracts of HeLa cells. Ribonuclease L cleaved HCV mRNA into fragments 200 to 500 bases in length. Ribonuclease L cleaved HCV mRNA predominately at UA and UU dinucleotides within loops of predicted stem-loop structures. HCV mRNAs from relatively interferon-resistant genotypes (HCV genotypes 1a and 1b) have fewer UA and UU dinucleotides than HCV mRNAs from more interferon-sensitive genotypes (HCV genotypes 2a, 2b, 3a, and 3b). HCV 2a mRNA, with 73 more UA and UU dinucleotides than HCV 1a mRNA, was cleaved by RNase L more readily than HCV 1a mRNA. In patients, HCV 1b mRNAs accumulated silent mutations preferentially at UA and UU dinucleotides during interferon therapy. These results suggest that the sensitivity of HCV infections to interferon therapy may correlate with the efficiency by which RNase L cleaves HCV mRNA.

Full Text

The Full Text of this article is available as a PDF (776.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barton D. J., Black E. P., Flanegan J. B. Complete replication of poliovirus in vitro: preinitiation RNA replication complexes require soluble cellular factors for the synthesis of VPg-linked RNA. J Virol. 1995 Sep;69(9):5516–5527. doi: 10.1128/jvi.69.9.5516-5527.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barton D. J., Flanegan J. B. Coupled translation and replication of poliovirus RNA in vitro: synthesis of functional 3D polymerase and infectious virus. J Virol. 1993 Feb;67(2):822–831. doi: 10.1128/jvi.67.2.822-831.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barton D. J., Morasco B. J., Flanegan J. B. Assays for poliovirus polymerase, 3D(Pol), and authentic RNA replication in HeLa S10 extracts. Methods Enzymol. 1996;275:35–57. doi: 10.1016/s0076-6879(96)75005-x. [DOI] [PubMed] [Google Scholar]
  4. Benoit De Coignac A., Bisbal C., Lebleu B., Salehzada T. cDNA cloning and expression analysis of the murine ribonuclease L inhibitor. Gene. 1998 Mar 16;209(1-2):149–156. doi: 10.1016/s0378-1119(98)00040-7. [DOI] [PubMed] [Google Scholar]
  5. Blight K. J., Rice C. M. Secondary structure determination of the conserved 98-base sequence at the 3' terminus of hepatitis C virus genome RNA. J Virol. 1997 Oct;71(10):7345–7352. doi: 10.1128/jvi.71.10.7345-7352.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brown E. A., Zhang H., Ping L. H., Lemon S. M. Secondary structure of the 5' nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res. 1992 Oct 11;20(19):5041–5045. doi: 10.1093/nar/20.19.5041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cabot B., Martell M., Esteban J. I., Sauleda S., Otero T., Esteban R., Guàrdia J., Gómez J. Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J Virol. 2000 Jan;74(2):805–811. doi: 10.1128/jvi.74.2.805-811.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cammà C., Craxì A. Chronic hepatitis C: retreatment of relapsers. An evidence-based approach. Semin Gastrointest Dis. 2000 Apr;11(2):115–121. [PubMed] [Google Scholar]
  9. Carroll S. S., Cole J. L., Viscount T., Geib J., Gehman J., Kuo L. C. Activation of RNase L by 2',5'-oligoadenylates. Kinetic characterization. J Biol Chem. 1997 Aug 1;272(31):19193–19198. doi: 10.1074/jbc.272.31.19193. [DOI] [PubMed] [Google Scholar]
  10. Cole J. L., Carroll S. S., Blue E. S., Viscount T., Kuo L. C. Activation of RNase L by 2',5'-oligoadenylates. Biophysical characterization. J Biol Chem. 1997 Aug 1;272(31):19187–19192. doi: 10.1074/jbc.272.31.19187. [DOI] [PubMed] [Google Scholar]
  11. Davis G. L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S. C., Trepo C., Shiffman M. L., Zeuzem S., Craxi A., Ling M. H. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1493–1499. doi: 10.1056/NEJM199811193392102. [DOI] [PubMed] [Google Scholar]
  12. De Mitri M. S., Mele L., Morsica G., Chen C. H., Sitia G., Gramenzi A., Andreone P., Alberti A., Bernardi M., Pisi E. Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies. J Med Virol. 2000 Feb;60(2):133–138. doi: 10.1002/(sici)1096-9071(200002)60:2<133::aid-jmv5>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  13. Desai S. Y., Patel R. C., Sen G. C., Malhotra P., Ghadge G. D., Thimmapaya B. Activation of interferon-inducible 2'-5' oligoadenylate synthetase by adenoviral VAI RNA. J Biol Chem. 1995 Feb 17;270(7):3454–3461. doi: 10.1074/jbc.270.7.3454. [DOI] [PubMed] [Google Scholar]
  14. Desai S. Y., Sen G. C. Effects of varying lengths of double-stranded RNA on binding and activation of 2'-5'-oligoadenylate synthetase. J Interferon Cytokine Res. 1997 Sep;17(9):531–536. doi: 10.1089/jir.1997.17.531. [DOI] [PubMed] [Google Scholar]
  15. Diamantis I., Vafiadis I., Voskaridou E., Dellatetsima J., Jäggi N., Gyr K., Battegay M. Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy. Eur J Gastroenterol Hepatol. 1998 Jan;10(1):75–79. doi: 10.1097/00042737-199801000-00014. [DOI] [PubMed] [Google Scholar]
  16. Dong B., Silverman R. H. A bipartite model of 2-5A-dependent RNase L. J Biol Chem. 1997 Aug 29;272(35):22236–22242. doi: 10.1074/jbc.272.35.22236. [DOI] [PubMed] [Google Scholar]
  17. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest. 1995 Jul;96(1):224–230. doi: 10.1172/JCI118025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Enomoto N., Sato C. Clinical relevance of hepatitis C virus quasispecies. J Viral Hepat. 1995;2(6):267–272. doi: 10.1111/j.1365-2893.1995.tb00040.x. [DOI] [PubMed] [Google Scholar]
  19. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J. C., Strazzera A., Chien D. Y., Munoz S. J., Balestrieri A. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000 Apr 14;288(5464):339–344. doi: 10.1126/science.288.5464.339. [DOI] [PubMed] [Google Scholar]
  20. Floyd-Smith G., Slattery E., Lengyel P. Interferon action: RNA cleavage pattern of a (2'-5')oligoadenylate--dependent endonuclease. Science. 1981 May 29;212(4498):1030–1032. doi: 10.1126/science.6165080. [DOI] [PubMed] [Google Scholar]
  21. Forns X., Purcell R. H., Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol. 1999 Oct;7(10):402–410. doi: 10.1016/s0966-842x(99)01590-5. [DOI] [PubMed] [Google Scholar]
  22. Gale M., Jr, Blakely C. M., Kwieciszewski B., Tan S. L., Dossett M., Tang N. M., Korth M. J., Polyak S. J., Gretch D. R., Katze M. G. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol. 1998 Sep;18(9):5208–5218. doi: 10.1128/mcb.18.9.5208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hartmann R., Norby P. L., Martensen P. M., Jorgensen P., James M. C., Jacobsen C., Moestrup S. K., Clemens M. J., Justesen J. Activation of 2'-5' oligoadenylate synthetase by single-stranded and double-stranded RNA aptamers. J Biol Chem. 1998 Feb 6;273(6):3236–3246. doi: 10.1074/jbc.273.6.3236. [DOI] [PubMed] [Google Scholar]
  24. Hovnanian A., Rebouillat D., Mattei M. G., Levy E. R., Marié I., Monaco A. P., Hovanessian A. G. The human 2',5'-oligoadenylate synthetase locus is composed of three distinct genes clustered on chromosome 12q24.2 encoding the 100-, 69-, and 40-kDa forms. Genomics. 1998 Sep 15;52(3):267–277. doi: 10.1006/geno.1998.5443. [DOI] [PubMed] [Google Scholar]
  25. Keeffe E. B., Dusheiko G. M., Tong M. J., Hollinger F. B., Heathcote E. J., McHutchison J., Albert D. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines Cell Mol Ther. 1999 Dec;5(4):211–216. [PubMed] [Google Scholar]
  26. Kolykhalov A. A., Agapov E. V., Blight K. J., Mihalik K., Feinstone S. M., Rice C. M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 1997 Jul 25;277(5325):570–574. doi: 10.1126/science.277.5325.570. [DOI] [PubMed] [Google Scholar]
  27. Kolykhalov A. A., Feinstone S. M., Rice C. M. Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. J Virol. 1996 Jun;70(6):3363–3371. doi: 10.1128/jvi.70.6.3363-3371.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Korth M. J., Katze M. G. Evading the interferon response: hepatitis C virus and the interferon-induced protein kinase, PKR. Curr Top Microbiol Immunol. 2000;242:197–224. doi: 10.1007/978-3-642-59605-6_10. [DOI] [PubMed] [Google Scholar]
  29. Li X. L., Blackford J. A., Hassel B. A. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol. 1998 Apr;72(4):2752–2759. doi: 10.1128/jvi.72.4.2752-2759.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lohmann V., Körner F., Dobierzewska A., Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol. 2001 Feb;75(3):1437–1449. doi: 10.1128/JVI.75.3.1437-1449.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Maitra R. K., McMillan N. A., Desai S., McSwiggen J., Hovanessian A. G., Sen G., Williams B. R., Silverman R. H. HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymes. Virology. 1994 Nov 1;204(2):823–827. doi: 10.1006/viro.1994.1601. [DOI] [PubMed] [Google Scholar]
  32. Martinand C., Salehzada T., Silhol M., Lebleu B., Bisbal C. The RNase L inhibitor (RLI) is induced by double-stranded RNA. J Interferon Cytokine Res. 1998 Dec;18(12):1031–1038. doi: 10.1089/jir.1998.18.1031. [DOI] [PubMed] [Google Scholar]
  33. Mathews D. H., Sabina J., Zuker M., Turner D. H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol. 1999 May 21;288(5):911–940. doi: 10.1006/jmbi.1999.2700. [DOI] [PubMed] [Google Scholar]
  34. McHutchison J. G., Gordon S. C., Schiff E. R., Shiffman M. L., Lee W. M., Rustgi V. K., Goodman Z. D., Ling M. H., Cort S., Albrecht J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485–1492. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  35. Merriam J. M., Rubenstein A. B., Klymkowsky M. W. Cytoplasmically anchored plakoglobin induces a WNT-like phenotype in Xenopus. Dev Biol. 1997 May 1;185(1):67–81. doi: 10.1006/dbio.1997.8550. [DOI] [PubMed] [Google Scholar]
  36. Miele M. B., Liu D. K., Kan N. C. Fractionation and characterization of 2',5'-oligoadenylates by polyacrylamide gel electrophoresis: an alternative method for assaying 2',5'-oligoadenylate synthetase. J Interferon Res. 1991 Feb;11(1):33–40. doi: 10.1089/jir.1991.11.33. [DOI] [PubMed] [Google Scholar]
  37. Molla A., Paul A. V., Wimmer E. Cell-free, de novo synthesis of poliovirus. Science. 1991 Dec 13;254(5038):1647–1651. doi: 10.1126/science.1661029. [DOI] [PubMed] [Google Scholar]
  38. Nakamura Y., Gojobori T., Ikemura T. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. 2000 Jan 1;28(1):292–292. doi: 10.1093/nar/28.1.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nilsen T. W., Maroney P. A., Baglioni C. Double-stranded RNA causes synthesis of 2',5'-oligo(A) and degradation of messenger RNA in interferon-treated cells. J Biol Chem. 1981 Aug 10;256(15):7806–7811. [PubMed] [Google Scholar]
  40. Nilsen T. W., Wood D. L., Baglioni C. Presence of 2',5'-oligo(A) and of enzymes that synthesize, bind, and degrade 2',5'-oligo(A) in HeLa cell nuclei. J Biol Chem. 1982 Feb 25;257(4):1602–1605. [PubMed] [Google Scholar]
  41. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol. 2001 Feb;75(3):1252–1264. doi: 10.1128/JVI.75.3.1252-1264.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Player M. R., Torrence P. F. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther. 1998 May;78(2):55–113. doi: 10.1016/S0163-7258(97)00167-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rebouillat D., Hovanessian A. G. The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J Interferon Cytokine Res. 1999 Apr;19(4):295–308. doi: 10.1089/107999099313992. [DOI] [PubMed] [Google Scholar]
  44. Rijnbrand R. C., Lemon S. M. Internal ribosome entry site-mediated translation in hepatitis C virus replication. Curr Top Microbiol Immunol. 2000;242:85–116. doi: 10.1007/978-3-642-59605-6_5. [DOI] [PubMed] [Google Scholar]
  45. Sakuma I., Enomoto N., Kurosaki M., Izumi N., Marumo F., Sato C. Differential effect of interferon on hepatitis C virus 1b quasispecies in the nonstructural protein 5A gene. J Infect Dis. 1999 Oct;180(4):1001–1009. doi: 10.1086/315000. [DOI] [PubMed] [Google Scholar]
  46. Sakuma I., Enomoto N., Kurosaki M., Marumo F., Sato C. Selection of hepatitis C virus quasispecies during interferon treatment. Arch Virol. 1996;141(10):1921–1932. doi: 10.1007/BF01718204. [DOI] [PubMed] [Google Scholar]
  47. Sarkar S. N., Bandyopadhyay S., Ghosh A., Sen G. C. Enzymatic characteristics of recombinant medium isozyme of 2'-5' oligoadenylate synthetase. J Biol Chem. 1999 Jan 15;274(3):1848–1855. doi: 10.1074/jbc.274.3.1848. [DOI] [PubMed] [Google Scholar]
  48. Sarrazin C., Berg T., Lee J. H., Teuber G., Dietrich C. F., Roth W. K., Zeuzem S. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol. 1999 Jun;30(6):1004–1013. doi: 10.1016/s0168-8278(99)80253-0. [DOI] [PubMed] [Google Scholar]
  49. Sarrazin C., Kornetzky I., Rüster B., Lee J. H., Kronenberger B., Bruch K., Roth W. K., Zeuzem S. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology. 2000 Jun;31(6):1360–1370. doi: 10.1053/jhep.2000.7987. [DOI] [PubMed] [Google Scholar]
  50. Schenborn E. T., Mierendorf R. C., Jr A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure. Nucleic Acids Res. 1985 Sep 11;13(17):6223–6236. doi: 10.1093/nar/13.17.6223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sharp T. V., Raine D. A., Gewert D. R., Joshi B., Jagus R., Clemens M. J. Activation of the interferon-inducible (2'-5') oligoadenylate synthetase by the Epstein-Barr virus RNA, EBER-1. Virology. 1999 May 10;257(2):303–313. doi: 10.1006/viro.1999.9689. [DOI] [PubMed] [Google Scholar]
  52. Silverman R. H., Skehel J. J., James T. C., Wreschner D. H., Kerr I. M. rRNA cleavage as an index of ppp(A2'p)nA activity in interferon-treated encephalomyocarditis virus-infected cells. J Virol. 1983 Jun;46(3):1051–1055. doi: 10.1128/jvi.46.3.1051-1055.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Taylor D. R., Shi S. T., Romano P. R., Barber G. N., Lai M. M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999 Jul 2;285(5424):107–110. doi: 10.1126/science.285.5424.107. [DOI] [PubMed] [Google Scholar]
  54. Wang C., Sarnow P., Siddiqui A. A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA. J Virol. 1994 Nov;68(11):7301–7307. doi: 10.1128/jvi.68.11.7301-7307.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wang C., Sarnow P., Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol. 1993 Jun;67(6):3338–3344. doi: 10.1128/jvi.67.6.3338-3344.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Wreschner D. H., James T. C., Silverman R. H., Kerr I. M. Ribosomal RNA cleavage, nuclease activation and 2-5A(ppp(A2'p)nA) in interferon-treated cells. Nucleic Acids Res. 1981 Apr 10;9(7):1571–1581. doi: 10.1093/nar/9.7.1571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Wreschner D. H., McCauley J. W., Skehel J. J., Kerr I. M. Interferon action--sequence specificity of the ppp(A2'p)nA-dependent ribonuclease. Nature. 1981 Jan 29;289(5796):414–417. doi: 10.1038/289414a0. [DOI] [PubMed] [Google Scholar]
  58. Yanagi M., Purcell R. H., Emerson S. U., Bukh J. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology. 1999 Sep 15;262(1):250–263. doi: 10.1006/viro.1999.9889. [DOI] [PubMed] [Google Scholar]
  59. Zein N. N., Rakela J., Krawitt E. L., Reddy K. R., Tominaga T., Persing D. H. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996 Oct 15;125(8):634–639. doi: 10.7326/0003-4819-125-8-199610150-00002. [DOI] [PubMed] [Google Scholar]
  60. Zylberberg H., Chaix M. L., Bréchot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med. 2000 May 16;132(10):845–846. doi: 10.7326/0003-4819-132-10-200005160-00029. [DOI] [PubMed] [Google Scholar]

Articles from RNA are provided here courtesy of The RNA Society

RESOURCES